Comparative diagnostic performance of [ 18 F] flurpiridaz PET and SPECT myocardial perfusion imaging (MPI): a systematic review and meta-analysis.
Muataz Kashbour, Sarah Amro, Eman Ayman Nada et al.
✦ AI-curated · Sources linked
In 30 seconds
[¹⁸F]flurpiridaz PET was compared to SPECT myocardial perfusion imaging (MPI) for diagnosing coronary artery disease (CAD) in a systematic review and meta-analysis of 3 trials involving 1476 patients. The study found that [¹⁸F]flurpiridaz PET had a pooled sensitivity of 76% and specificity of 71% for ≥50% stenosis, outperforming SPECT's sensitivity of 61% and specificity of 76%.
Key findings
- [¹⁸F]flurpiridaz PET showed a sensitivity of 76% and specificity of 71% for detecting ≥50% stenosis.
- For ≥70% stenosis, [¹⁸F]flurpiridaz PET had a sensitivity of 87% compared to 73% for SPECT.
- Image quality was significantly better for [¹⁸F]flurpiridaz PET with a relative risk of 1.29 for rest images.
- Patients with BMI ≥30kg/m² had a sensitivity of 74% for [¹⁸F]flurpiridaz PET versus 61% for SPECT.
Why it matters
The findings highlight the potential of [¹⁸F]flurpiridaz PET as a more effective diagnostic tool for CAD, particularly in women and obese patients, which may influence imaging choices in clinical practice.
What to keep in mind
The analysis is based on a limited number of studies, which may affect the robustness of the conclusions.